Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07045935 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment

Study acronym: ProBOLIC
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jun 10, 2025 to Sep 16, 2025v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized, active-controlled, parallel-arm, single-blind trial is to compare the effects of Dopamine agonists (DA) therapy targeting different established treatment strategies on glucose metabolism assessed by an oral glucose tolerance test.
Trial Details
NCT Number NCT07045935
Lead Sponsor University Hospital, Basel, Switzerland
Conditions
(from sponsor)		 Prolactinoma
Related terms Hyperprolactinemia, Prolactin Deficiency, Isolated, Prolactinoma
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov